People with Duchenne muscular dystrophy (DMD) frequently live well into adulthood. Advances in treatment have significantly increased the life expectancy for this condition. The median life expectancy ...
Trodelvy plus Keytruda may maintain QOL and delay physical decline in PD-L1-positive mTNBC patients. The combination therapy showed improved progression-free survival and reduced symptom burden ...
People with Duchenne muscular dystrophy have a shorter-than-average life expectancy due to changes in muscles that affect breathing, heart activity, and other functions. However, treatment advances ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results